Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of Bavituximab Plus Docetaxel in Stage IIIb/IV Non-Squamous NSCLC
2013-003953-13Phase 3Terminated
- Sponsor
- Avid Bioservices, Inc.
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Non-small cell lung cancer (NS-NSCLC) comparing Bavituximab plus docetaxel with Placebo plus docetaxel (2 arms). Primary endpoint: Overall survival. Started Mar 2014; status: terminated.
02
Drugs
bavituximab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2013-003953-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003953-13.